7-(4-fluoro-benzyloxy)-3-(2-methoxy-ethyl)-3H-quinazolin-4-one | 713511-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-(4-fluoro-benzyloxy)-3-(2-methoxy-ethyl)-3H-quinazolin-4-one
• 英文别名: 7-[(4-Fluorophenyl)methoxy]-3-(2-methoxyethyl)quinazolin-4-one
• CAS: 713511-00-3
• 化学式: C₁₈H₁₇FN₂O₃
• 分子量: 328.343
• InChiKey: UHFGVUPGEDYFAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  500.8±60.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] 3H-QUINAZOLIN-4-ONE DERIVATIVES<br/>[FR] DERIVES DE 3H-QUINAZOLINE-4-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004054985A1

  公开（公告）日：2004-07-01

  This invention relates to 3H-quinazolin-4-one derivatives as defined in the specification and claims, to a process for their preparation, to pharmaceutical compositions comprising them and to their use as selective monoamine oxidase B inhibitors.

  本发明涉及规范和声明中定义的3H-喹唑啉-4-酮衍生物，它们的制备方法，包含它们的制药组合物以及它们作为选择性单胺氧化酶B抑制剂的用途。
• 3H-quinazolin-4-one derivatives as MAO-B inhibitors
  申请人：——

  公开号：US20040142951A1

  公开（公告）日：2004-07-22

  This invention relates to 3H-quinazolin-4-one derivatives as defined in the specification and claims, to a process for their preparation, to pharmaceutical compositions comprising them and to their use as selective monoamine oxidase B inhibitors.

  本发明涉及规范和要求中定义的3H-喹唑啉-4-酮衍生物，它们的制备方法，包含它们的制药组合物和它们作为选择性单胺氧化酶B抑制剂的用途。
• 3H-QUINAZOLIN-4-ONE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1572666A1

  公开（公告）日：2005-09-14
• TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES
  申请人：Oryzon Genomics SA

  公开号：EP2195029A2

  公开（公告）日：2010-06-16
• MAO-B INHIBITORS USEFUL FOR TREATING OBESITY
  申请人：McElroy Francis John

  公开号：US20070078172A1

  公开（公告）日：2007-04-05

  The invention provides a method of treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of an irreversible MAO-B inhibitor.